Thomas Horn-Spirohn

Title: Thomas Horn-Spirohn: Innovator in Cancer Treatment

Introduction

Thomas Horn-Spirohn is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. With a total of 3 patents, his work focuses on innovative combinations of inhibitors that target specific pathways in cancer cells.

Latest Patents

Horn-Spirohn's latest patents include a pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib. This combination is designed for the treatment or prevention of cancer. The patent details a method of administering a therapeutically effective amount of this combination to patients. Another significant patent involves a pharmaceutical combination of the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib. This combination also aims to treat or prevent cancer, showcasing Horn-Spirohn's commitment to advancing cancer therapies.

Career Highlights

Thomas Horn-Spirohn is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on developing innovative solutions for cancer treatment. His contributions have been instrumental in pushing the boundaries of pharmaceutical research.

Collaborations

Throughout his career, Horn-Spirohn has collaborated with esteemed colleagues such as Giordano Caponigro and Joseph Lehar. These collaborations have fostered a productive environment for innovation and have led to significant advancements in cancer treatment.

Conclusion

Thomas Horn-Spirohn is a prominent figure in the pharmaceutical industry, particularly in the realm of cancer treatment. His innovative patents and collaborations reflect his dedication to improving patient outcomes through advanced therapies.